https://www.austinpx.com/kc-entry/choosing-the-best-amorphous-dispersion-path-before-it-costs-you/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/beyond-solvents-the-future-of-sustainable-amorphous-dispersion-development/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/how-cdmos-turn-undruggable-into-developable/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/from-in-silico-to-in-vivo-why-development-strategy-now-determines-ai-era-success/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/re-thinking-the-pipeline-development-in-the-age-of-ai/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/solving-the-problem-of-insolubility-the-medicine-maker-interview-series-3-part/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/ai-might-find-the-molecule-but-delivery-decides-whether-it-becomes-a-medicine/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/how-to-solve-complex-pediatric-dosing-challenges-using-tailored-solutions/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/collaborative-innovation-in-cdmos-interview-series-with-pharmaceutical-technology-5-part/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/pushing-the-boundaries-overcoming-formulation-and-manufacturing-challenges-ebook-w-pharmaceutical-technology/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/from-disruption-to-reinvention-the-story-of-api-in-capsule-technology-and-its-future/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/precision-without-a-playbook-how-agile-cdmos-enable-personalised-drug-development/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/sustainability-in-pharma-manufacturing-strategic-benefits-of-going-green/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/partnerships-to-be-precise/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/building-resilience-cdmo-strategies-for-drug-supply-chain-stability/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/pharma-trends-and-predictions-for-2025-an-incoming-ceos-perspective/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/a-shifting-cdmo-landscape-the-rise-of-high-science-high-touch/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/breaking-all-the-rules-pushing-the-boundaries-of-lipinskis-rule-of-5/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/cdmos-and-small-molecule-challenges-navigating-the-impact-of-the-inflation-reduction-act/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/kinetisol-technology-a-sustainable-and-efficient-revolution-in-bioavailability-enhancement/2026-07-21T13:30:05+00:00https://www.austinpx.com/kc-entry/pushing-the-boundaries-of-drug-development-is-lipinskis-rule-of-five-still-relevant/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/winning-strategies-for-oral-dosage-form-development-and-manufacturing/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/less-mess-less-stress-best-expressed-a-superior-alternative-to-spray-drying/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/dave-miller-pioneer-in-pharmaceutical-innovation/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/pharma-matters-qa-austinpx-talking-next-gen-amorphous-dispersion-technology/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/trends-in-amorphous-solid-dispersion-drug-products-approved-by-the-u-s-fda-between-2012-and-2023/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/how-difficult-is-it-to-scale-up-an-amorphous-dispersion-xtalks-article/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/how-prioritizing-sustainability-efforts-yields-long-term-growth-in-drug-manufacturing/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/how-sustainable-practices-in-pharma-drive-long-term-growth/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/dcat-sustainability-leaders-ebook/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/what-sets-austinpx-apart-a-cdmo-differentiated-by-their-history/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/from-confidence-to-concern-the-shift-in-spray-drying-sentiment/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/converting-from-a-spray-dried-dispersion-to-a-kinetisol-formulation-in/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/data-driven-development-of-clofazimine-a-high-drug-load-pediatric-mini-tablet/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/using-kinetisol-technology-to-improve-an-abandoned-prostate-cancer-medication-galeterone/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/tailoring-exposure-for-efficacy-next-generation-pk-optimization-with-kinetisol-enabled-bae-and-cr-design/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/formulation-strategies-for-enabling-undevelopable-compounds-poster/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/redefining-drug-like-properties-with-kinetisol/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/kinetisol-in-action-scalable-sustainable-amorphous-dispersion-manufacturing/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/austinpx-live-inside-austinpx-live-company-overview-episode-1/2026-07-21T13:30:07+00:00https://www.austinpx.com/kc-entry/outsourcedpharma-live-austinpx-facility-tour-capabilities-presentation/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/overview-kinetisol-technology-from-austinpx/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/austinpx-live-episode-6-re-thinking-asd-development-designing-for-scale-from-day-one/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/austinpx-live-episode-5-re-thinking-asd-development-when-your-molecule-breaks-the-rules/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/austinpx-live-episode-4-from-brick-dust-to-breakthrough-the-power-of-enabled-formulation/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/austinpx-live-episode-3-from-molecule-to-milestone-fast-track-formulation/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/austinpx-live-episode-2-navigating-complexity-tailored-analytical-preclinical-services/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/austinpx-live-episode-1-inside-austinpx-live-company-overview/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/overcoming-late-stage-formulations-manufacturing-challenges-with-kinetisol-technology/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/de-risking-development-guiding-formulation-strategy-with-macroflux-to-predict-human-outcomes-of-kinetisol-processed-etravirine/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/how-difficult-is-it-to-scale-up-an-amorphous-dispersion-xtalks-interview/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/oral-dosage-innovation-for-pediatric-drug-delivery/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/optimizing-drug-loading-in-amorphous-solid-dispersions-maximizing-bioavailability-while-minimizing-pill-burden/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/optimizing-amorphous-solid-dispersions-overcoming-scale-up-challenges-with-next-generation-technologies/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/why-kinetisol-technology-is-disrupting-spray-drying/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/kinetisol-technology-scale-up-approach/2026-07-21T13:30:09+00:00https://www.austinpx.com/kc-entry/amorphous-solid-dispersions-development-trends-challenges-and-the-future/2026-07-21T13:30:09+00:00